Angioedema without urticaria: novel findings which must be measured in clinical setting.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
20
2
2020
medline:
4
9
2021
entrez:
20
2
2020
Statut:
ppublish
Résumé
Angioedema without urticaria is composed of an increasing subtype's variety and presents a challenging diagnosis. This review summarizes the subtypes recently described and subsequent new findings helpful within their classification. New methods to measure cleaved high molecular weight kininogen and activated plasma kallikrein have emerged as potential biochemical tests to identify bradykinin-mediated angioedema. Three new subtypes of hereditary angioedema (HAE) with normal C1 inhibitor were described in the past two years: HAE due to mutation in plasminogen gene, in kininogen gene, and in angiopoietin-1 gene; implicating the fibrinolytic and contact systems, and the regulation of vasculature, respectively. The understanding of some mechanisms in angioedema has been improved, compatible to the dominant-negative for some C1 inhibitor variants; furthermore, the increased activation of truncated F12 mutants by plasma kallikrein; and the diminished binding of angiopoietin-1 to its receptor. The validation of biomarkers for the contact system activation could be beneficial in differentiating bradykinin - from histaminergic-mediated angioedema. Currently, the available laboratorial tests are still somewhat restricted to the evaluation of the complement activation and the mediators of nonhistaminergic and nonbradykinin-mediated angioedema remain to be identified.
Identifiants
pubmed: 32073435
doi: 10.1097/ACI.0000000000000633
pii: 00130832-202006000-00007
doi:
Substances chimiques
ANGPT1 protein, human
0
Angiopoietin-1
0
Biomarkers
0
KNG1 protein, human
0
Kininogens
0
Plasminogen
9001-91-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
253-260Références
Cicardi M, Zuraw BL. Angioedema due to bradykinin dysregulation. J Allergy Clin Immunol Pract 2018; 6:1132–1141.
Betschel S, Badiou J, Binkley K, et al. The International/Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol 2019; 15:72.
Veronez CL, Campos RA, Constantino-Silva RN, et al. Hereditary angioedema-associated acute pancreatitis in C1-inhibitor deficient and normal C1-inhibitor patients: case reports and literature review. Front Med (Lausanne) 2019; 6:80.
Nettis E, Di Leo E, Racanelli V, et al. Idiopathic nonhistaminergic angioedema: a single-center real-life experience from Italy. Allergy 2019; 74:1389–1392.
Lara-Marquez ML, Christiansen SC, Riedl MA, et al. Threshold-stimulated kallikrein activity distinguishes bradykinin: from histamine-mediated angioedema. Clin Exp Allergy 2018; 48:1429–1438.
Veronez CL, Nascimento FD, Melo KR, et al. The involvement of proteoglycans in the human plasma prekallikrein interaction with the cell surface. PLoS One 2014; 9:e91280.
Verhoef JJ, Barendrecht AD, Nickel KF, et al. Polyphosphate nanoparticles on the platelet surface trigger contact system activation. Blood 2017; 129:1707–1717.
Oschatz C, Maas C, Lecher B, et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011; 34:258–268.
Beinrohr L, Harmat V, Dobó J, et al. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem 2007; 282:21100–21109.
Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109:1057–1063.
Veronez CL, Maghsodi S, Todiras M, et al. Endothelial B2-receptor overexpression as an alternative animal model for hereditary angioedema. Allergy 2019; 74:1998–2002.
Germenis AE, Margaglione M, Pesquero JB, et al. International consensus on the use of genetics in the management of hereditary angioedema. J Allergy Clin Immunol Pract 2019; pii: S2213-2198(19)30869-4. doi: 10.1016/j.jaip.2019.10.004. [Epub ahead of print].
doi: 10.1016/j.jaip.2019.10.004.
pii: s2213-2198(19)30869-4.
Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71:206–215.
Ferrara AL, Bova M, Petraroli A, et al. Hereditary angioedema attack: what happens to vasoactive mediators? Int Immunopharmacol 2020; 78:106079.
Kaplan AP, Pawaskar D, Chiao J. C1 inhibitor activity and angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol Pract 2019; pii: S2213-2198(19)30868-2. doi: 10.1016/j.jaip.2019.10.003.
doi: 10.1016/j.jaip.2019.10.003
pii: s2213-2198(19)30868-2.
Veronez CL, Aabom A, Martin RP, et al. Genetic variation of kallikrein-kinin system and related genes in patients with hereditary angioedema. Front Med (Lausanne) 2019; 6:28.
Castellano G, Divella C, Sallustio F, et al. A transcriptomics study of hereditary angioedema attacks. J Allergy Clin Immunol 2018; 142:883–891.
Stenson PD, Mort M, Ball EV, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet 2017; 136:665–677.
Ponard D, Gaboriaud C, Charignon D, et al. SERPING1 mutation update: mutation spectrum and C1 inhibitor phenotypes. Hum Mutat 2020; 41:38–57.
Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106:1147–1154.
Loules G, Zamanakou M, Parsopoulou F, et al. Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency. Gene 2018; 667:76–82.
Veronez CL, da Silva ED, Lima Teixeira PV, et al. Genetic analysis of hereditary angioedema in a Brazilian family by targeted next generation sequencing. Biol Chem 2016; 397:315–322.
Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356:213–217.
Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol 2006; 154:542–545.
Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343:1286–1289.
Bork K, Wulff K, Steinmüller-Magin L, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy 2018; 73:442–450.
Bafunno V, Firinu D, D’Apolito M. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol 2018; 141:1009–1017.
Bork K, Wulff K, Rossmann H, et al. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin. Allergy 2019; 74:2479–2481.
Bork K, Wulff K, Meinke P, et al. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011; 141:31–35.
Veronez CL, Serpa FS, Pesquero JB. A rare mutation in the F12 gene in a patient with ACE inhibitor-induced angioedema. Ann Allergy Asthma Immunol 2017; 118:743–745.
Björkqvist J, de Maat S, Lewandrowski U, et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 2015; 125:3132–3146.
Ivanov I, Matafonov A, Sun MF, et al. A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain. Blood 2019; 133:1152–1163.
Belbezier A, Hardy G, Marlu R, et al. Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: three additional French families. Allergy 2018; 73:2237–2239.
Yakushiji H, Hashimura C, Fukuoka K, et al. A missense mutation of the plasminogen gene in hereditary angioedema with normal C1 inhibitor in Japan. Allergy 2018; 73:2244–2247.
Recke A, Massalme EG, Jappe U, et al. Identification of the recently described plasminogen gene mutation p.Lys330Glu in a family from Northern Germany with hereditary angioedema. Clin Transl Allergy 2019; 9:9.
Bodian DL, Vilboux T, Hauser NS. Genotype-first analysis of a generally healthy population cohort supports genetic testing for diagnosis of hereditary angioedema of unknown cause. Allergy Asthma Clin Immunol 2019; 15:32.
d’Apolito M, Santacroce R, Colia AL, et al. Angiopoietin-1 haploinsufficiency affects the endothelial barrier and causes hereditary angioedema. Clin Exp Allergy 2019; 49:626–635. doi: 10.1111/all.14160. [Epub ahead of print]. PMID: 31860755.
doi: 10.1111/all.14160.
Bova M, Suffritti C, Bafunno V, et al. Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor. Allergy 2019; doi: 10.1111/all.14160. [Epub ahead of print].
doi: 10.1111/all.14160.
Zanichelli A, Azin GM, Wu MA, et al. Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency. J Allergy Clin Immunol Pract 2017; 5:1307–1313.
Bork K, Staubach-Renz P, Hardt J. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate. Orphanet J Rare Dis 2019; 14:65.
López-Lera A, Garrido S, Nozal P, et al. Serum complexes between C1INH and C1INH autoantibodies for the diagnosis of acquired angioedema. Clin Exp Immunol 2019; 198:341–350.
Brown T, Gonzalez J, Monteleone C. Angiotensin-converting enzyme inhibitor-induced angioedema: a review of the literature. J Clin Hypertens (Greenwich) 2017; 19:1377–1382.
Hubers SA, Kohm K, Wei S, et al. Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol 2018; 142:1636.e5–1639.e5.
Jeon J, Lee YJ, Lee SY. Effect of icatibant on angiotensin-converting enzyme inhibitor-induced angioedema: a meta-analysis of randomized controlled trials. J Clin Pharm Ther 2019; 44:685–692.
Ali HA, Lomholt AF, Mahmoudpour SH, et al. Genetic susceptibility to angiotensin-converting enzyme-inhibitor induced angioedema: a systematic review and evaluation of methodological approaches. PLoS One 2019; 14:e0224858.
Hofman ZL, van West N, Hack CE, et al. High occurrence of antihistamine resistance in patients with recurrent idiopathic angioedema. Clin Transl Allergy 2019; 9:35.
Bucher MC, Petkovic T, Helbling A, Steiner UC. Idiopathic nonhistaminergic acquired angioedema: a case series and discussion of published clinical trials. Clin Transl Allergy 2017; 7:27.
Brunetta E, Shiffer D, Folci M, et al. Omalizumab for idiopathic nonhistaminergic angioedema: evidence for efficacy in 2 patients. Case Reports Immunol 2018; 2018:8067610.
Farkas H, Veszeli N, Kajdácsi E, et al. Nuts and bolts’ of laboratory evaluation of angioedema. Clin Rev Allergy Immunol 2016; 51:140–151.
Tarzi MD, Hickey A, Forster T, et al. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin Exp Immunol 2007; 149:513–516.
Charest-Morin X, Betschel S, Borici-Mazi R, et al. The diagnosis of hereditary angioedema with C1 inhibitor deficiency: a survey of Canadian physicians and laboratories. Allergy Asthma Clin Immunol 2018; 14:83.
Gompels MM, Lock RJ, Unsworth DJ, et al. Misdiagnosis of hereditary angio-oedema type 1 and type 2. Br J Dermatol 2003; 148:719–723.
Karim Y, Griffiths H, Deacock S. Normal complement C4 values do not exclude hereditary angioedema. J Clin Pathol 2004; 57:213–214.
Tange CE, Kaur A, Verma N, et al. Quantification of human C1 esterase inhibitor protein using an automated turbidimetric immunoassay. J Clin Lab Anal 2019; 33:e22627.
Haslund D, Ryø LB, Seidelin Majidi S, et al. Dominant-negative SERPING1 variants cause intracellular retention of C1 inhibitor in hereditary angioedema. J Clin Invest 2019; 129:388–405.
Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy 2017; 72:300–313.
Aaborn A, Andersen KE, Fagerberg C, et al. Clinical characteristics and real-life diagnostic approaches in all Danish children with hereditary angioedema. Orphanet J Rare Dis 2017; 12:55.
Wagenaar-Bos IG, Drouet C, Aygoren-Pursun E, et al. Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. J Immunol Methods 2008; 338:14–20.
Li HH, Busse P, Lumry WR, et al. Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema. J Allergy Clin Immunol Pract 2015; 3:200–205.
Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69:602–616.
Joseph K, Bains S, Tholanikunnel BG, et al. A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin-forming enzymes. Allergy 2015; 70:115–119.
Joseph K, Constantino-Silva RN, Grumach AS, et al. Reply. J Allergy Clin Immunol 2017; 139:1720–1721.
Marlu R, Deroux A, Du-Thanh A, et al. Normal PAI-2 level in French FXII-HAE patients. J Allergy Clin Immunol 2017; 139:1719–1720.
Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol 2013; 131:1491.e25–1493.e25.
Suffritti C, Zanichelli A, Maggioni L, et al. High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency. Clin Exp Allergy 2014; 44:1503–1514.
Baroso R, Sellier P, Defendi F, et al. Kininogen cleavage assay: diagnostic assistance for kinin-mediated angioedema conditions. PLoS One 2016; 11:e0163958.
Hofman ZL, de Maat S, Suffritti C, et al. Cleaved kininogen as a biomarker for bradykinin release in hereditary angioedema. J Allergy Clin Immunol 2017; 140:1700.e8–1703.e8.
Zhang G, Sexton DJ, Faucette RR, et al. 2D-LC-MS/MS to measure cleaved high-molecular-weight kininogen in human plasma as a biomarker for C1-INH-HAE. Bioanalysis 2017; 9:1477–1491.
Qiu T, Chiuchiolo MJ, Whaley AS, et al. Gene therapy for C1 esterase inhibitor deficiency in a Murine Model of Hereditary angioedema. Allergy 2019; 74:1081–1089.